Conquering Your ‘Personal Everest’

Milind Soman tells us about I Can You Can, an adventure reality show that he is hosting, and his trekking experience to Everest Base Camp with the contestants

Smoking and Everest Base Camp trekking — two quite unrelated and ironic things in one sentence, aren’t they? Adventure reality show I Can You Can on online video platform Viu combines these two in an interesting manner. Produced by BBC India, I Can You Can, a captivating anti-smoking initiative went online on December 17.

Made in partnership with Nicotex, the six-episode series will be telecast every Sunday. It will be available on Viu and will be televised as a simulcast on National Geographic.

The show is hosted by actor, model and athlete Milind Soman, and showcases the journey of six people, including three who want to quit smoking and three who have already quit. “The interesting part of the journey is the interaction between the smokers and the ones who have quit and their efforts to not just conquer Everest Base Camp, but also their own ‘personal Everests’,” says Milind.

Having time and again raised the bar for fitness and health, Milind says, “Hosting I Can You Can was an exhilarating experience for me. We shot some breathtaking sequences in the unexplored terrains on our way to Everest Camp. I have been a chainsmoker in the past and I could relate to what the contestants of the show have been through. I think when something is so easily accessible and addictive, it just makes it tougher to put a stop to it. I hope with this show, viewers will realise how important a healthy lifestyle is and be encouraged to kick the butt.”

What made him quit smoking, we ask. “I began smoking when I had just entered the industry. Given our hectic schedules, the endless wait at shooting sights and other such things pushed me to begin smoking, given the number of smokers around me. All these years even while I was smoking, I knew it was wrong, always. One fine day, I just thought that I can’t continue this. One bad habit leads to a worse habit and similarly, one good habit leads to a better one. That was it. It wasn’t easy quitting, I took two years to give up completely but I did it and can feel the difference,” he says.

On the show, Milind says that he got an opportunity to interact with the six contenders and learn from them too. With an engaging and contemporary format of an adventure series, the weekly show aims at reaching out to millennials and hopes for each to conquer their own Everest.

“A lot of sharing of experiences happened among all of us,” he says adding that the six contenders on the show were chosen through a contest.

Remind him of the date — December 16, and the coincidence that he recently did a short film on Vijay Diwas — when Pakistani troops surrendered to the Indian Army after the 1964 war, Milind smiles and says, “Yes! I absolutely enjoyed doing that short film and love taking up such interesting projects.” When BBC India approached him with I Can You Can too, he “jumped at the opportunity”, he says.

Ask him about his next immediate plan, and he quickly replies, “Don’t even ask, because I don’t have any. I don’t believe in planning too much. I do what I like and enjoy doing it like that,” he concludes.

This article originally appeared on Sakal Times

For more such blogs follow us on Twitter, Facebook, LinkedIn.

Cipla Q3 FY18 Results Reflect Continuously Improving Quality Of Earnings Backed By Strong Momentum Across Key Regions

Press Release

Cipla Limited (BSE: 500087, NSE: CIPLA) today announced its unaudited consolidated financial results for the quarter ended December 31, 2017. The Company reported quarterly revenues of Rs 3,914 crores, a growth of 7% on a year-on-year basis, with EBITDA at 20.9%, growing 21% on a year-on-year basis. EBITDA margins have been improving continuously driven by cost optimization across all spend lines despite R&D getting stepped up to 7.6% of sales during the quarter. When adjusted for the one-offs during the quarter, the Profit After Tax rose by ~25% on a year-on-year basis. The Company reported healthy growth across businesses in India, South Africa, API, Europe and Sub-Saharan Africa markets.

“This has been one of our better quarters. Key performance metrics look healthy and are inline
with the internal targets we set for ourselves. We are stepping up our investments in R&D
which has resulted in approvals for differentiated products in the US”
– Umang Vohra
MD and Global CEO, Cipla Ltd

Download the PDF.

For more such blogs follow us on TwitterFacebookLinkedIn.

Programme On Nutritious Food Organised By Cipla

Samala Hema, Seethaphalmandi Corporator attended the programme about nutritious food organised by Cipla industries at Jyothi Model High School, here on Wednesday. As a part of the programme, experts from the health industry held a session to explain parents’ about child health and immunity.

The corporator too encouraged children and the parents to adopt a hygienic and healthy lifestyle to protect young lives. Later, the corporator along with officials of the GHMC and senior TRS leaders comprising Laxman Rao, ward member of the constituency interacted with the residents of Beedal Basthi as a part of the Basthi Baata programme to know their problems.

This article originally appeared in The Hans India.

For more such blogs follow us on TwitterFacebookLinkedIn.

Cipla Receives Final Approval for a Generic Version of Gilead’s Viread®

Press Release

Cipla Ltd, a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients, announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Tenofovir Disoproxil Fumarate Tablets, 300mg, from the United States Food and Drug Administration (USFDA) to market a generic version of Gilead Sciences’ Viread® Tablets, 300mg.

Cipla’s Tenofovir Disoproxil Fumarate Tablets, 300mg, are AB-rated generic equivalents of Gilead Sciences’ Viread® Tablets, 300mg, and are indicated in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in adults and paediatric patients 12 years of age and older. Cipla is excited to add this important antiretroviral product to its growing portfolio of ARVs in the U.S.

The product will be available for commercial shipment in the U.S. immediately. Viread® Tablets,
300mg, had U.S. sales of approximately $725M for the 12-month period ending November 2017,
as reported by IMS Health.

For more such blogs follow us on TwitterFacebookLinkedIn.

India’s Cancer Cases Far Lower Than Those In The West, Yet Death Rate Higher

India’s cancer graphs tell two distinct stories. The first holds out hope as India’s cancer incidence is far lower than developed nations such as Denmark and the US. If cancer strikes over 300 out of every 100,000 population in Denmark, the corresponding number in India hovers around 80. But the second Indian cancer story is worrisome: cancer manages to get the upper hand in almost 70% of cases in India. A study in the medical journal, The Lancet, in 2014 indicated only 30% of India’s cancer patients survive for over five years.

So while India has lower cancer rates than many other countries, it has a high death rate. Check the World Health Organisation’s Globocan 2012 report’s analysis for breast cancer: only 1 out every 5 or 6 women newly diagnosed with breast cancer died in the US, but corresponding figures in India stood at 1out of every 2 patients.

Experts said early detection could go a long way in reducing the high death rate caused due to illiteracy, fear and taboos. “In India, almost 50% of all cancers are seen in late stages. This is the reason our death rate is higher than western countries,” said senior medical oncologist Shona Nag.

Maximum cancer patients succumb to lung, head and neck and breast cancers. “We lose almost 80% of all patients detected with lung cancer. The death rate due to breast cancer world over is 20%, but we lose over 50% of our breast cancer patients,” Nag said.

Almost 80% of cervical cancer patients are diagnosed in stage 3-4 in India, but the West has almost eradicated this cancer due to regular pap smear tests. Given India’s population, it is impossible to scan everybody. “Self-breast exams and clinical exams involving community workers or ancillary health professionals are hence crucial,” she added.

Lack of awareness is the main cause for late detection. “In the western world, the culture is openness and they are more aware. Though we have facilities, we cannot reach out to such a huge population. Almost all cancers are detected at late stage in India mainly because of lack of awareness and social stigma,” said medical oncologist Anantbhushan Ranade.

Cancer surgeon Anupama Mane said, “We have women with 10cm lumps who come to us late because the lump didn’t hurt or cause pain so they did not think a check was needed.” Moreover, men don’t discuss women’s health. “So a blood stain or excessive bleeding is dismissed and not taken up as cause for worry,” Mane said. Early detection is key to reduce mortality. “It is important to diagnose cancer early because then you have a chance at curing it. The spread and extent of it make it harder to control,” said oncosurgeon Snita Sinukumar. Lack of a dedicated health care system is one of the big reasons for higher deaths. “Just like Aadhar, we need to make it compulsory to invest in one’s own healthcare,” Sinukumar added.

This article originally appeared on The Times of India

For more such blogs follow us on Twitter, Facebook, LinkedIn.